{"id":"pl9643-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition increases intracellular cAMP levels in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism reduces ocular surface inflammation and is being developed for dry eye disease and other inflammatory ocular conditions.","oneSentence":"PL9643 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production in ocular tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:15.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Ocular surface inflammation"}]},"trialDetails":[{"nctId":"NCT05201170","phase":"PHASE3","title":"A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye","status":"COMPLETED","sponsor":"Palatin Technologies, Inc","startDate":"2021-12-30","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":575},{"nctId":"NCT04268069","phase":"PHASE2","title":"Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye","status":"COMPLETED","sponsor":"ORA, Inc.","startDate":"2020-02-14","conditions":"Dry Eye Disease","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active study medication"],"phase":"phase_3","status":"active","brandName":"PL9643 Ophthalmic Solution","genericName":"PL9643 Ophthalmic Solution","companyName":"ORA, Inc.","companyId":"ora-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PL9643 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production in ocular tissues. Used for Dry eye disease, Ocular surface inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}